Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Global Narcolepsy Treatment Market Size study, by Drug Type (Vasopressors, CNS Stimulants, Decongestants, Serotonin Reuptake Inhibitors), by End-Use (Retail Pharmacies, Drug Stores, E-commerce) and Regional Forecasts 2022-2028
... USD 4.10 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5.00 % over the forecast period 2022-2028. Narcolepsy is a chronic neurological disorder that is associated with ... Read More
-
Cat Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Cat Allergy (Immunology) pipeline landscape. Cat allergy is an allergic reaction to one or more allergens produced by cats. Symptoms include sneezing, runny or stuffy nose, facial pain (from nasal ... Read More
-
Grass Pollen Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape. Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions, such ... Read More
-
Anal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Anal Cancer (Oncology) pipeline landscape. Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of ... Read More
-
B-Cell Chronic Lymphocytic Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape. B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). ... Read More
-
Diabetic Gastroparesis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape. Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts ... Read More
-
Dystrophin (DMD) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It acts as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and ... Read More
-
Oral Mucositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape. Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, ... Read More
-
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... pipeline Target constitutes close to 48 molecules. Out of which approximately 37 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Drugs In Development, 2022, outlays ... Read More
-
Alpha-1 Antitrypsin Deficiency (A1AD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) pipeline landscape. Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that ... Read More
-
Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The ... Read More
-
Blepharitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Blepharitis (Ophthalmology) pipeline landscape. Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, ... Read More
-
Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the Juvenile Macular Degeneration (Ophthalmology) pipeline landscape. Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form ... Read More
-
Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape. Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular ... Read More
-
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... FXN or EC 1.16.3.1) pipeline Target constitutes close to 21 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Frataxin Mitochondrial - Drugs In Development, ... Read More
-
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... recently published report 'Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Drugs In Development, 2022'; Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 25 ... Read More
-
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Update Summary Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded ... Read More
-
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... - Drugs In Development, 2022, provides an overview of the Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline landscape. Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role ... Read More
-
Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)
... Online Provider, and Retail Pharmacy) The non-alcoholic steatohepatitis (NASH) market is projected to reach US$ 24,266.81 million by 2028 from US$ 1,631.92 million in 2021; it is expected to grow at a CAGR of 47.1% ... Read More
-
Periodontitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Periodontitis (Mouth And Dental Disorders) pipeline landscape. Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, ... Read More
-
Viral Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape. Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from ... Read More
-
Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Leiomyosarcoma (Oncology) pipeline landscape. Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, ... Read More
-
Synovial Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape. Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, ... Read More
-
Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Osteosarcoma (Oncology) pipeline landscape. Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone ... Read More
-
Bronchopulmonary Dysplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape. Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms of BPD include ... Read More
Research Assistance
